Q2 2026 13F · SEC CIK 78003
Pfizer Inc
CorporationFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $170.4M
- Reported positions
- 17
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 1.8 yrs
Pfizer Inc is a corporation that reported 17 positions worth $170.4M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Allogene Therapeutics Inc (ALLO, 27.5%), Celcuity Inc (CELC, 17.3%), Arvinas Inc (ARVN, 16.2%).
Pfizer Inc holdings all 17 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| ALLOAllogene Therapeutics Inc | 27.5% | +0.0% | $46.9M |
| CELCCelcuity Inc | 17.3% | +0.0% | $29.6M |
| ARVNArvinas Inc | 16.2% | +0.0% | $27.7M |
| PYXSPyxis Oncology Inc | 11.4% | +0.0% | $19.5M |
| WVEWave Life Sciences Ltd | 6.4% | +0.0% | $10.9M |
| BHVNBiohaven Ltd | 4.7% | +0.0% | $8.0M |
| CRBUCaribou Biosciences Inc | 4.6% | +0.0% | $7.9M |
| SPROSpero Therapeutics Inc | 3.1% | +0.0% | $5.3M |
| ZNTLZentalis Pharmaceuticals Inc | 2.3% | +0.0% | $3.9M |
| ORICOric Pharmaceuticals Inc | 2.1% | -92.2% | $3.6M |
| CRDFCardiff Oncology Inc | 1.8% | +0.0% | $3.0M |
| ZURAZura Bio Ltd | 1.7% | -81.0% | $2.9M |
| AGMBAgomab Therapeutics NV | 0.6% | +0.0% | $1.0M |
| BOLTBolt Biotherapeutics Inc | 0.1% | +0.0% | $134K |
| NXTCNextcure Inc | 0.0% | -71.1% | $73K |
| DNAGinkgo Bioworks Holdings Inc | 0.0% | +0.0% | $30K |
| SENSSenseonics Hldgs Inc | 0.0% | +0.0% | $12K |
What Pfizer Inc bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
- ORIC Oric Pharmaceuticals Inc-92.2% shares
- ZURA Zura Bio Ltd-81.0% shares
- NXTC Nextcure Inc-71.1% shares
Sold out
- QTTB Q32 Bio Incwas 0.3%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +5.9% /yr
- S&P 500 +20.1%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $170.4M | 17 |
| Q1 2026 | $238.8M | 18 |
| Q4 2025 | $236.5M | 18 |
| Q3 2025 | $437.5M | 21 |
| Q2 2025 | $576.2M | 21 |
| Q1 2025 | $500.8M | 21 |
| Q4 2024 | $2.6B | 23 |
Questions about Pfizer Inc's portfolio
What stocks does Pfizer Inc own?
Pfizer Inc's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 17 positions worth $170.4M. The largest are Allogene Therapeutics Inc (ALLO) at 27.5%, Celcuity Inc (CELC) at 17.3%, Arvinas Inc (ARVN) at 16.2%, Pyxis Oncology Inc (PYXS) at 11.4% and Wave Life Sciences Ltd (WVE) at 6.4%.
What did Pfizer Inc buy last quarter?
Pfizer Inc opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did Pfizer Inc sell last quarter?
In Q2 2026, Pfizer Inc sold all of Q32 Bio Inc (QTTB), Oric Pharmaceuticals Inc (ORIC) (-92.2% shares), Zura Bio Ltd (ZURA) (-81.0% shares) and Nextcure Inc (NXTC) (-71.1% shares), compared with its Q1 2026 filing.
When is Pfizer Inc's next 13F filing due?
13F filings are due 45 days after each quarter ends. Pfizer Inc's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.